Answers are grounded in this paper and cite their sources.
Purpose Sacituzumab govitecan (SG) improves survival in patients with previously treated metastatic triple-negative breast cancer (mTNBC); however, its high drug cost raises concerns regarding cost-effectiveness. This study evaluated the cost-effectiveness of SG compared with single-agent chemotherapy from the perspective of the Japanese public healthcare payer. Methods A partitioned survival analysis model comprising progression-free, progressed disease, and death states was developed using efficacy data from the ASCENT trial. Long-term overall survival and progression-free survival were estimated by fitting parametric survival distributions to reconstructed individual patient data. Direct medical costs were estimated using official drug prices and the JMDC Claims Database, and utility values were obtained from a Japanese study. Costs and quality-adjusted life years (QALYs) were discounted at 2% annually over a lifetime horizon. One-way and probabilistic sensitivity analyses and scenario analyses were performed. Price thresholds for SG corresponding to Japanese cost-effectiveness reference thresholds were also estimated. Results SG provided 0.83 QALYs compared with 0.59 QALYs for single-agent chemotherapy, resulting in an incremental gain of 0.24 QALYs. Total healthcare costs were JPY 18,533,967 and JPY 4,700,042, respectively, yielding an incremental cost of JPY 13,833,926. The resulting incremental cost-effectiveness ratio (ICER) was JPY 56,546,430 per QALY, substantially exceeding the Japanese reference threshold of JPY 15 million per QALY. The ICER remained above this threshold in all sensitivity and scenario analyses, and the probability that SG was cost-effective at this threshold was 0%. To achieve ICERs of JPY 15 million, JPY 11.25 million, and JPY 7.5 million per QALY, the SG price would need to be reduced by 76.45%, 83.35%, and 90.25%, respectively. Conclusion SG improved survival and QALYs compared with single-agent chemotherapy but was not cost-effective at its current price from the perspective of the Japanese public healthcare payer. Substantial price reductions would be required for SG to meet the reference thresholds used in the Japanese cost-effectiveness evaluation system. These findings provide quantitative evidence to inform pricing, healthcare resource allocation, and decision-making regarding SG in Japan.
No takes yet. Share an insight, caveat, or question.
Yamaguchi-Naruoka et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: